Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by DrHolidayon Oct 02, 2018 5:44pm
137 Views
Post# 28732847

Understanding & reiterating the highlights

Understanding & reiterating the highlightsAs per the previous 6 posts by Rocketred2015, the extremely bullish fundamental base case highlights are glowing hot in today's press release. To reiterate and condense into one nutshell are these 6 posts in one. I welcome you back Rocketred2015, and I know that you have made money while ICO was consolidating and are ready to redeploy your capital for the big pay day. Congratulations to all longs, who stayed the course although the voyage was a bit stormy. Our friend juansito never gave up and held patiently. He is now in the crow's nest and soon we will sight land, (land ho) where we will find ICO treasure and valuable spices such as Oral B Amphotericin.To all those who bailed out near the low and lost hope, you have my sympathies, but you should have had more testicular fortitude and waited because I told you that a major news release was forthcoming.
The turnaround for ICO is now in full rally mode in my personal opinion.

Here are the 6 highlights reiterated and condensed into one post for you.:


1.world-class group of clinical experts in the anti-fungal arena and expects to announce a clinical advisory board 
 
2.iCo now expects to present its full phase 1 data analysis to the public in Q4 2018
 
3.The FDA has also recently granted orphan drug designation to iCo-008 BP
 
4.iCo may receive up to $32-million in milestone payments, beginning with a material payment upon first dose in a pivotal BP trial
 
5.preliminary data from its second phase 2 study in ulcerative colitis (UC) in Q1 2019
 
6.Should be market moving event back to 25 cents ? How about 1 dollar Rocketred2015?

DOC
<< Previous
Bullboard Posts
Next >>